主页   l   登录   l   
  
首页
公司新闻


THE WALL STREET JOURNAL

来源:Lilly Asia Ventures  作者:ijian  时间:2015-10-20  


介绍:“Eli Lilly and China’s Innovent Expand Partnership” The two companies define the distribution rights for up to three co- developed, experimental cancer drugs By: Ezequiel Minaya October 12, 2015
“Eli Lilly and China’s Innovent Expand Partnership”
The two companies define the distribution rights for up to three co-developed, experimental cancer drugs By: Ezequiel Minaya
October 12, 2015
Eli Lilly & Co. and Innovent Biologics Inc. said late Sunday that they have expanded their collaboration deal and defined the distribution rights for up to three co-developed, experimental cancer drugs.
According to a joint statement, Eli Lilly would market the drugs outside of China with Innovent marketing the drugs inside the Asian country, subject to a Lilly opt-in right.
Under the expanded agreement, Innovent could receive more than $1 billion if the products reach certain development, regulatory and sales milestones, both inside and outside of China. Further financial terms weren't disclosed.
In March, the companies formed their partnership, creating one of the broadest collaborations ever forged between a large Western drug maker and a Chinese biotechnology company.
Indianapolis-based Lilly at the time said it would pay $56 million upfront to Innovent, a four-year-old startup near Shanghai, to co-develop at least three cancer drugs—including one from Lilly’s research labs and two from Innovent.
Also at the time, Lilly said it could pay more than $400 million to Innovent if one of the Innovent drugs hit certain development and commercial goals.
The deal gave Lilly a local partner to help speed up its introduction of new biotechnology-style drugs in the fast-growing Chinese market. It also expanded Lilly’s efforts in two hot areas of drug development: drugs that unleash the body’s
immune system to fight cancer, and so-called “biosimilar” drugs, or knockoffs of brand-name biotech drugs.

 中国上海黄浦区湖滨路168号企业天地3号楼2909室  
 +86 21 2316 9588  
   
copyright © 2012-2015 Lilly Asia Ventures all rights reserved.
信息产业部ICP备案号:沪ICP备11028519号-1